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Background: The duration between first symptom and a cancer diagnosis is important because, if shortened, may
lead to earlier stage diagnosis and improved cancer outcomes. We have previously developed a tool to measure
this duration in newly-diagnosed patients. In this two-phase study, we aimed further improve our tool and to
conduct a trial comparing levels of anxiety between two modes of delivery: self-completed versus
researcher-administered.
Methods: In phase 1, ten patients completed the modified tool and participated in cognitive debrief interviews. In
phase 2, we undertook a Randomised Controlled Trial (RCT) of the revised tool (Cancer Symptom Interval Measure
(C-SIM)) in three hospitals for 11 different cancers. Respondents were invited to provide either exact or estimated
dates of first noticing symptoms and presenting them to primary care. The primary outcome was anxiety related to
delivery mode, with completeness of recording as a secondary outcome. Dates from a subset of patients were
compared with GP records.
Results: After analysis of phase 1 interviews, the wording and format were improved. In phase 2, 201 patients were
randomised (93 self-complete and 108 researcher-complete). Anxiety scores were significantly lower in the
researcher-completed group, with a mean rank of 83.5; compared with the self-completed group, with a mean rank
of 104.0 (Mann-Whitney U = 3152, p = 0.007). Completeness of data was significantly better in the
researcher-completed group, with no statistically significant difference in time taken to complete the tool between
the two groups. When comparing the dates in the patient questionnaires with those in the GP records, there was
evidence in the records of a consultation on the same date or within a proscribed time window for 32/37 (86%)
consultations; for estimated dates there was evidence for 23/37 consultations (62%).
Conclusions: We have developed and tested a tool for collecting patient-reported data relating to appraisal
intervals, help-seeking intervals, and diagnostic intervals in the cancer diagnostic pathway for 11 separate cancers,
and provided evidence of its acceptability, feasibility and validity. This is a useful tool to use in descriptive and
epidemiological studies of cancer diagnostic journeys, and causes less anxiety if administered by a researcher.
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Mortality from cancer is worse in the UK than most
other European countries [1,2]. The reasons for this are
multi-factorial, but diagnostic delays and consequent
later stage diagnoses are likely to be major contributory
factors [3]. Interventions to reduce diagnostic delays,
which result in a less advanced stage at diagnosis, have
the potential to improve cancer survival [4], although
tumour biology is also important. Interventions need to
account for lead-time bias whereby more timely diagnosis
may improve survival by bringing forward the diagnosis
rather than delaying mortality. Diagnostic delays (perhaps
better referred to as ‘time-intervals’ since there is not al-
ways a ‘delay’) may occur throughout the cancer diagnos-
tic pathway. Whilst a minority of patients are diagnosed
through screening (in some cancers), and some present as
an emergency to A&E or via inter-specialty referral (with-
out consulting in primary care), the majority of diagnoses
are made for patients who follow the ‘typical’ cancer jour-
ney involving symptomatic presentation through primary
care [5-8]. In the UK, and elsewhere, there has been a
drive in policy towards early, and more timely diagnosis of
cancer; for example the National Awareness and Early
Diagnosis Initiative (England), the Detect Cancer Early
Initiative (Scotland) and the International Cancer Bench-
marking Partnership (several countries).
The duration between first symptom and cancer diag-
nosis is important because, if shortened, it may lead to
earlier stage diagnosis and improved cancer outcomes
[9,10]. Measurement is complex because some symp-
toms are simply present or absent (e.g. a breast lump or
rectal bleeding), whilst others are not instantly notice-
able (e.g. tiredness or weight loss). Most studies report-
ing both ‘appraisal intervals’ (‘time taken to interpret
bodily changes/symptoms’) and ‘help seeking’ intervals
(time taken to act on those interpretations and seek help’)
[11] use tools that ignore existing models of patient
behaviour [12,13], are poorly or inadequately validated,
and are open to bias. There is a well-recognised need to
develop valid instruments for measuring ‘delay’ [11],
and this is one of the recommendations of the Aarhus
checklist on the design and reporting of early cancer
diagnosis studies that has recently been published [14].
We previously reported the first phase of the pilot
work to develop and pilot a postal version of such a tool
(the ‘DELAYS’ tool) [15]. This questionnaire was tailored
to individual cancers and asked patients to recall the
dates of the onset of symptoms (based on referral guid-
ance symptoms) and their presentation to primary care,
in addition to socio-demographic and health questions.
One issue that arose (predominantly from phone calls
from potential respondents to the research team) was
the potential anxiety that may be generated by use of the
tool (for example asking patients to recall when they firstexperienced symptoms may cause upset if they feel that
their diagnosis was unduly delayed). The other main issue
was that the response rate to the postal questionnaire was
only moderate (46.2%).
Hence, the aim of this paper is to report the further
development of the ‘DELAYS’ tool, now renamed the
Cancer Symptom Interval Measure (C-SIM), through in–
depth cognitive testing, and its testing in a randomised
controlled trial (RCT) comparing different methods of
delivery (on the premise that anxiety may be less in the
presence of a researcher). The primary objective of this
RCT was to compare the level of patients’ anxiety between
two methods of delivery (self-completed and researcher-
completed) of administering a tool, which measures time
from first symptom to cancer diagnosis. Secondary objec-
tives of this trial were: to compare the difference in com-
pletion rates between two methods of delivery; to describe
the process, and difficulties associated with either method
of delivery; to compare the information about symptoms
from the patient tool with that obtained from primary care
records. Hence, we gathered further information in the
trial about the quality of the tool, primarily acceptability
(does it provoke undue anxiety; completion rates, com-
pletion time) and feasibility (problems with administra-
tion). Focused qualitative evaluation presented in the
paper (cognitive interviews) adds to the evidence for the
measure’s face validity, and the comparison of self-
report against records adds to the measure’s criterion
validity [16,17].
Methods
Phase 1. Further development of the tool and cognitive
debriefing interviews with cancer patients.
The aim of Phase 1 was to improve the previously re-
ported DELAYS tool [15], to make it suitable for use in
the trial, building on the previous work and making it
more acceptable, more likely to be completed, and less
likely to cause anxiety.This further development was in-
formed by the cognitive aspects of survey methodology
approach [18-20] and utilised the findings from system-
atic review evidence regarding survey response [21-23].
We recruited ten patients to complete the modified tool
and participate in cognitive debriefing interviews. They
were either allocated to self-completed or researcher-
completed mode. In addition to asking patients questions
about symptoms related to their own cancer, we also asked
about the wording of questions relating to symptoms of
other cancers. Post completion, the participants under-
went a cognitive debriefing interview. Areas identified
as problematic in the initial piloting [15] were specifically
addressed.
Key interview probes were used that directly and
intentionally match the steps of the standard cognitive
model for survey response (comprehension, retrieval,
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were:
 What the respondent believed the question to be
asking.
 What specific words and phrases meant to the
respondent.
 The type of information the respondent needed to
recall in order to answer the question.
 What types of strategy the respondent used to
retrieve information.
 Whether the respondent devoted sufficient mental
effort to answer accurately and thoughtfully.
 Whether the respondent wanted to tell the truth, or
whether the respondent wanted to say something
that made him/her look better (i.e. social
desirability).
 Whether the respondent matched his or her
internally generated answer to the response
categories given by the survey question.
The data were analysed to identify dominant trends
across interviews and to identify ‘discoveries’ (unexpected
problems that were only present in one interview, but
were important). Findings from these interviews informed
further re-wording of the tool. Lastly, we worked with
three patient groups within the North East Wales NHS
Trust (now part of Betsi Cadwaladr University Health
Board) to ensure that the tool captured the diagnostic
journey in a way that was acceptable and easy to
understand.
The final tool
This revised tool (C-SIM), in 11 separate versions (lung,
colorectal, breast, pancreatic, gastric/oesophageal, renal/
bladder, endometrial/cervical, haematological, ovarian,
prostate and testicular cancers), was then tested in the
RCT. It comprised questions concerning the timing of
the onset and presentation of symptoms. Respondents
were invited to provide either exact or estimated dates
of first noticing symptoms and presenting them to pri-
mary care. These covered cancer site specific symptom
questions (variable between cancers); and four general
cancer symptom questions (loss of appetite, weight
loss, fatigue and ‘feeling different’). One question asked
whether they had been sent for any GP-initiated tests.
Further questions covered employment status, educational
qualifications, ethnicity, whether they lived alone, co-
morbidity, smoking status, family risk of cancer. Finally,
as part of the RCT a measure of anxiety, the State-Trait
Anxiety Inventory (STAI) was added as the main out-
come measure [24]. The tool was produced on double
sided A4 paper and was 11 pages long (see Additional
file 1–the colorectal tool, and Additional file 2–thecancer specific questions for the other 10 versions). The
final version of the tool built upon that previously
reported [15] in that we:
 Removed the calendar landmarking tool, because
participants reported that they didn’t find it useful
 Added a personal letter from the Principal.
Investigator inside the front cover, to try to improve
the response rate [22].
 Improved the format of the boxes for the questions
regarding symptom duration.
 Added more tests (CT scan & ultrasound scan), that
were missing from the original.
 Made multiple changes to the wording to make it
more patient-centred and easier to understand.
Phase 2. Randomised controlled trial of method of
delivery of the tool.
Setting and participants
The trial took place in the three district general hospitals
in North Wales (Wrexham Maelor Hospital, Ysbyty
Gwynedd, and Ysbyty Glan Clywd), now all part of Betsi
Cadwaladr University Health Board. Fieldwork was under-
taken by research officers/nurses from the NISCHR Clin-
ical Research Collaboration. The research officers/nurses
attended MDT meetings for the following cancers: breast,
colorectal, lung, gynaecological, urological, upper GI, and
haematological. At these meetings all patients with new
primary diagnoses were alerted to the researcher, who
then liaised with the clinical nurse specialists and other
members of the clinical teams in order to assess eligibility
for inclusion. Patients were eligible if they had a new diag-
nosis of one of the 11 cancers, were aged 18 years or above
(with no upper age limit), were neither too ill nor close to
death at diagnosis, were not detected by screening (some
cervix, breast and colorectal), and were mentally and
linguistically competent to complete the tool.
Eligible patients were then sent a letter from the clinical
team inviting participation, enclosing a patient infor-
mation sheet, a return FREEPOST envelope and a con-
tact form. The researchers then contacted patients
who responded positively and arranged to meet them
in order to obtain consent (for data collection and access
to primary care records), randomisation and tool comple-
tion. Reminders letters were sent after two weeks.
Participants randomised to the self-completion arm
were handed the final tool (see above) and asked to
complete it. For those randomised to the researcher-
completion arm, the researcher sat with the participant
in a quiet place and went through the tool with them,
reading out the questions and entering their answers.
Identical tools were used for both groups. All of the re-
searchers received training to ensure that the delivery of
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in response to questions for both groups were permitted.
The trial was conducted from February to December
2009. Data were entered using Cardiff TeleForm (optical
character recognition system); 22 questionnaires (two
for each cancer site) were manually checked.
Randomisation
Patients were randomised to either the researcher-
completed or the self-completed mode. A computer gener-
ated random number sequence based on random permuted
blocks of sizes 4, 6 and 8 was used. Allocation concealment
was done by the controlled use of sequentially numbered
opaque envelopes, stratified by cancer site and by hospital,
except for: pancreatic, testicular and ovarian cancer where
the expected prevalence was too small to stratify by hospital
and a block size of 4 was used to minimise the risk of
chance imbalance; and haematological, endometrial/cervix
that were stratified by hospital but were also randomised
using a block size of 4.
Outcome measures
Measuring anxiety
We used the six-item State-Trait Anxiety Inventory (STAI)
to determine whether respondents had anxiety related to
questionnaire completion [24]. This has a low-burden, and
was designed to assess short-term fluctuations in anxiety.
Each item was scored 1-4, with a total score out of 24,
with higher scores indicating higher anxiety.
Process evaluation
After completion of the tool, the researcher completed a
brief sheet for each patient comprising the following
questions (with answer options):
 How long did it take the patient to compete the
questionnaire? (<5 minutes, between 5 and 10.
minutes, between 11 and 15 minutes, >15 minutes)
 Where did the patient complete the questionnaire?
(separate room, open area, while receiving
treatment).
 The researcher answered one further question for
the self-completed group only: ‘Did the patient ask
for any help?’ (Y/N). This was to capture data relat-
ing to help sought when it had not been offered.
The researcher answered two further questions for
the researcher-completed group only. These were a
subjective report of difficulty and anxiety observed
whilst the researcher was completing the tool with
each patient:
 Did the patient find any of the questions difficult?
(Y/N).
Was the patient made anxious? (Y/N).Data analysis
Analysis of primary outcome
The primary outcome when comparing the method of
delivery was anxiety, with the analysis carried out blind
to treatment allocation. We aimed to transform the data
to produce an approximately normal distribution and
undertake parametric tests; if not possible then non-
parametric testing was undertaken. Missing items were
imputed (see findings).
Analysis of secondary outcomes
Completeness of questionnaire The difference in com-
pleteness between the two methods of delivery were
compared (z statistic) on questions common to all of the
respondents. Hence we analysed data for:
 The four generic cancer questions. If the respondent
ticked the ‘yes’ box for having the particular
symptom, they were then assessed as to whether the
rest of the question was entered completely. If they
entered dates for first noticing and first reporting
(whether exact or estimated), or they reported that
they didn’t tell their GP or nurse, it was regarded as
‘complete’. Any less than this was regarded as ‘not
complete’.
 The demographic questions.
Process and difficulties From the post-completion sheets,
we determined the process of and difficulties associated
with both methods of delivery. This was descriptive other
than X2 for comparison of tool completion between modes
of delivery.
Comparison of recall of date of first presentation
against GP records We sought to obtain evidence of
criterion validity by comparing the dates of consultation
recorded by the measure from up to 60 patients against
their GP records. A protocol was developed to identify
40-50 consecutive completed questionnaires, ensuring
that there were at least 10 patients from each centre
and at least three from each cancer site. Patients were
excluded if they had the reported symptoms for more
than two years (because unlikely to represent the first
presentation of cancer). With patient consent we con-
tacted their GP, and asked them to complete a template.
We validated the date of reported first presentation of
each symptom, for both exact dates and estimated dates.
For exact dates, we asked GPs whether there was a con-
sultation on that particular day, or within a two-week
window either side. For estimated dates, we developed a
protocol for calculating a ‘pseudo-exact’ time-window
from the estimated date (see Additional file 3), and pro-
vided the GP with this time window for searching. We
also asked the date of the actual consultation according
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one symptom per consultation (we chose the first one
that the patient listed on their questionnaire).
Time intervals in the diagnostic journey Whilst the
actual time intervals in the diagnostic journey are not
reported in this paper, we developed, a protocol for chan-
ging reported estimated dates into pseudo-exact dates that
permit the calculation of time intervals based upon the
responses obtained (Additional file 4).
Sample size
The primary aim of this study was to detect a difference
in anxiety between the two methods of delivery of the
tool, with the completion rates as a secondary outcome.
150 patients per group (total 300), with a 95% CI (with a
comparative completion rate of 75%) would allow us to
detect a difference between groups on response rates
assuming a difference of 10% (95% CI +/-9%). An overall
completion rate of 75% would give 225 questionnaires
for analysis of anxiety. This would give a 95% CI for the
difference in log anxiety for the two modes of total
width 0.16 (0.08 from the mean to the limit). This is
based on a SD of log anxiety of 0.3 (based on previous
studies).
Results
Consent was obtained from 201 patients, all were rando-
mised and completed questionnaires were received from
all 201 participants (93 from self-completed and 108 from
the researcher-completed) (see Figure 1: CONSORT flowInvited to parti
(Met inclus
Analysed (n=93)
Excluded from analysis (give reasons) (n=0)
Allocated to self-completed (n=93) 
Allocatio
Analys
Con
Random
Enrolment
Figure 1 CONSORT 2010 flow diagram.diagram). A further 22 patients initially expressed an
interest in taking part in the trial, but were not contacted
further, because we anticipated reaching our target sample
size.
1 Group similarity at baselinecip
ion
n
is
sen
isaThe comparison between the two groups at baseline
is shown in Table 1 which shows that there were no
important differences between them.
2 Analysis of primary outcome
The STAI scores were not normally distributed and
could not be transformed into a normal distribution
by either log, exponential or square root
transformation. Consequently non-parametric analysis
was undertaken, with and without imputation of
individual data if the STAI score was missing
(median values imputed). 18 (9%) missing values
were replaced with the median value seven; this was
carried out to allow us to assess the effect of missing
values. Without imputation of missing data for the
researcher-completed group (n = 107) the mean
rank was 83.5; for the self-completed group (n = 76)
the mean rank was 104.0 (Mann-Whitney U = 3152,
p = 0.007). The median STAI score before replacing
missing values were: researcher completed group
7.0 (IQR 3); self-completed group 8 (IQR 7). With
imputation of missing data for the researcher-
completed group (n = 108) the mean rank was 91.9;
for the self-completed group (n = 93) the mean rank
was 111.5 (Mann-Whitney U = 4042, p = 0.014).
Hence STAI scores were significantly higher in theate (n=538) 
 criteria)
Excluded (n=337)
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Table 1 Baseline comparison between groups
Self-
completed
Researcher-
completed
n = 93 n = 108
Cancer site
Breast 28 (30.1%) 28 (25.9%)
Colorectal 15 (16.1%) 15 (13.9%)
Upper GI 5 (5.4%) 4 (3.7%)
Haematological 10 (10.8%) 10 (9.3%)
Pancreas 2 (2.2%) 3 (2.8%)
Testicle 1 (1.1%) 1 (0.9%)
Lung 11 (11.8%) 15 (13.9%)
Ovary 1 (1.1%) 3 (2.8%)
Prostate 15 16.1%) 21 (19.4%)
Renal/bladder 2 (2.2%) 3 (2.8%)
Endometrium/cervix 3 (3.2%) 5 (4.6%)
Age (years)
Mean (SD) 65.3 (11.3) 63.6 (12.2)
Gender
Male 45 (48.4%) 56 (51.9%)
Female 48 (51.6%) 52 (48.1%)
Employment
Employed full time 23 (24.7%) 17 (15.7%)
Employed part time 5 (5.4%) 12 (11.1%)
Self employed full time 6 (6.5%) 2 (1.9%)
Self employed part time 2 (2.2%) 8 (7.4%)
Unemployed 1 (1.1%) 2 (1.9%)
Retired 44 (47.3%) 59 (54.6%)
Sick/disabled 3 (3.2%) 3 (2.8%)
Looking after family/home 4 (4.3%) 2 (1.9%)
Other 2 (2.2%) 3 (2.8%)
Missing 3 (3.2%) 0 (0.0%)
Educational level
GCSE/O Level 19 (20.4%) 16 (14.8%)
A Level 5 (5.4%) 5 (4.6%)
Diploma 12 (12.9%) 12 (11.1%)
Degree/Higher degree 15 (16.1%) 20 (18.5%)
Other 11 (11.8%) 23 (21.3%)
None 26 (28.0%) 29 (26.9%)
Missing 5 (5.4%) 3 (2.8%)
Ethnicity
White British 79 (84.9%) 85 (78.7%)
White 11 (11.8%) 13 (12.0%)
White Irish 0 (0.0%) 1 (0.9%)
Other white 1 (1.1%) 8 (7.4%)
Table 1 Baseline comparison between groups (Continued)
Indian 0 (0.0%) 1 (0.9%)
Missing 2 (2.2%) 0 (0.0%)
Domestic status
Alone 20 (21.5%) 21 (19.4%)
Spouse/partner (+/- others) 63 (67.7%) 81 (75.0%)
Child/ren (+/- grandchildren) 5 (5.4%) 3 (2.8%)
Sibling/s 0 (0.0%) 1 (0.9%)
Parents 1 (1.1%) 0 (0.0%)
Friends 1 (1.1% 0 (0.0%)
Other 1 (1.1%) 1 (0.9%)
Missing 2 (2.2%) 1 (0.9%)
Co-morbidities
Previous cancer 6 (6.5%) 8 (7.4%)
Diabetes 9 (9.7%) 6 (5.6%)
COPD 3 (3.2%) 7 (6.5%)
Asthma 7 (7.5%) 16 (14.8%)
Other lung disease 1 (1.1%) 2 (1.9%)
Heart disease 11 (11.8%) 18 (16.7%)
Arthritis 16 (17.2%) 18 (16.7%)
Peptic ulcer 0 (0.0%) 3 (2.8%)
Irritable bowel syndrome 8 (8.6%) 9 (8.3%)
Inflammatory bowel disease 6 (6.5%) 5 (4.6%)
Anxiety or depression 19 (20.4%) 23 (21.3%)
Smoking
Current smoker 12 (12.9%) 16 (14.8%)
Ex-smoker 43 (46.2%) 55 (50.9%)
Never smoked 36 (38.7%) 37 (34.3%)
Missing 2 (2.2%) 0 (0.0%)
At risk of cancer because of family history
Yes 26 (28.0%) 23 (21.3%)
No 65 (65.9%) 84 (77.8%)
Missing 2 (2.2%) 1 (0.9%)
Time between diagnosis and completion (days)
Mean (SD) 85.5 (54.4) 102.4 (62.3)
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replacing missing values with the median were:
researcher completed group 7.0 (IQR 3);
self-completed group 7 (IQR 5.5).
3 Analysis of secondary outcome
Completeness of recording
The completeness of recording for the four generic
cancer questions is shown in Table 2. Although
numbers were small, the completeness of recording
was significantly better in the researcher-completed
group for one of the four generic symptoms
Table 2 Completeness of recording for the four generic
cancer symptoms
Number of patients
reporting this symptoms
Complete
data
Incomplete
data
z
statistic
p
Fatigue or tiredness
Researcher-completed
(n = 55)
53 2
Self-completed (n = 37) 34 3 −0.99 0.32
Unexplained weight loss
Researcher-completed
(n = 29)
28 1
Self-completed (n = 24) 23 1 −0.14 0.89
Decrease in appetite
Researcher-completed
(n = 25)
25 0
Self-completed (n = 23) 18 5 −2.80 0.005
Feeling different in yourself
Researcher-completed
(n = 35)
35 0
Self-completed (n = 29) 27 2 −1.64 0.10
Ta
D
Em
Ed
Et
Do
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6-
ST
ST
ST
ST
ST
ST
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demographic and STAI items are shown in Table 3.
4 Process of administering the tool
Duration of completion is shown in Table 4. This
showed no significant difference between the groups
(X2 = 2.23, p = 0.33). A greater proportion of
participants in the researcher-completed group took
>15 minutes. Help was provided to 46/93 (49.5%) of
the self-complete group. The researchers reported
that only 10/108 (9.3%) of the researcher-completed
group found the questions difficult. The researchersble 3 Missing data regarding the demographic questions a
Self-completed
n = 93
emographic questions
ployment 3 (3.2%)
ucational level 5 (5.4%)
hnicity 2 (2.2%)
mestic status 2 (2.2%)
oking 2 (2.2%)
risk of cancer (family history) 2 (2.2%)
item STAI
AI item 1 7 (7.5%)
AI item 2 14 (15.1%)
AI item 3 17 (18.3%
AI item 4 10 (10.8%)
AI item 5 13 (14.0%)
AI item 6 14 (15.1%)administering the tool did not report that any partic-
ipants in the researcher-completed group were made
anxious. The tool was completed in a separate room
for 122 (60.1%), in an open area for 53 (26.4%), and
whilst receiving treatment for eight (4.0%). Data
were missing for 18 (9.0%).
5 Comparison of patient questionnaires against GP
records
Data from 51 patients were compared against their
GP records (30 from the researcher-completed
group, and 21 from the self-completed group). Of
these: 16 had breast cancer; six colorectal; six lung;
four endometrial; three each for haematological,
pancreatic, prostate, and renal/bladder; and two
testicular. The 51 patients had 74 consultations
available for comparison with the GP records. 28
patients had one consultation available, 13 had two,
five had three, three had four, and two had five. The
findings are shown in Figure 2. This shows that
there was greater evidence of consultations being
recorded in the GP records for participants who
reported an exact date rather than for those who
reported an estimated date. For exact dates there
was evidence in the GP records of a consultation on
the same date or within the proscribed time window
for 32/37 (86%) consultations. For estimated dates
there was evidence for 23/37 (62%) consultations
within the proscribed time window.
Discussion
Summary of main findings
We have developed the Cancer Symptom Interval Meas-
ure (C-SIM) for collecting patient-reported data relatingnd STAI items
Researcher-
completed
n = 108
z statistic P
0 (0.0%) 1.88 0.06
3 (0.9%) 0.94 0.35
0 (0.0%) 1.53 0.13
1 (0.9%) 0.71 0.48
0 (0.0%) 1.53 0.13
1 (0.9%) 0.71 0.48
0 (0.0%) 2.90 0.004
0 (0.0%) 4.18 0.000
0 (0.0%) 4.64 0.000
0 (0.0%) 4.64 0.000
1 (0.9%) 3.63 0.0003
0 (0.0%) 4.18 0.000
Table 4 How long did it take the patient to compete the
questionnaire?
Self-completed Researcher-
completed
n = 108
X2 P
n = 93
5-10 minutes 16 (17.2%) 11 (10.2%) 2.23 0.33
11-15 minutes 35 (37.6%) 43 (39.8%)
>15 minutes 38 (40.9%) 50 (46.3%)
Missing 4 (4.3%) 4 (3.7%)
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tic intervals in the cancer diagnostic pathway for 11 separ-
ate cancers. This tool is easy to use and quick to complete.
It has evidence for acceptability, feasibility, face validity
and criterion validity. The main findings from the RCT
were that there were lower anxiety levels in the
researcher-completed group. It is not known whether the
higher level of anxiety in the self-completed group was a
result of the cancer diagnosis, or the completion of the
questionnaire. Data completeness was also greater for the
researcher-completed group for some of the items.
Discussion of the findings within the context of the
literature
There are very few reports of the development of mea-
sures to measure diagnostic times in cancer [14]. We are
not aware of any other studies that specifically measure
anxiety within this context. Hence it is difficult to know
whether the relatively elevated anxiety in the self-complete
group is specific to this tool. A recent review demon-
strated that there is a small but significant difference
in subjective outcomes reported either through self-
completed or interviewer-completed modes [23]. SoFigure 2 Validation of patient questionnaires against GP records.the validity of response is partly driven by that feature
of data collection mode. Because of that it may be that
some of the difference in anxiety found between forms
of completion in this study could be attributable not
only to the calming (or similar) effect of the researcher,
but also due to associated response bias. For example,
this could be that patients giving answers to researchers
do not want to show their feelings whilst those self-
completing forms are being more ‘honest’–a form of social
desirability bias. Unger-Saldana et al have recently re-
ported the development and validation of a questionnaire
to assess treatment delays in breast cancer [25]. Their
researcher-administered tool was aimed at lower socio-
economic groups, and included many domains about the
diagnostic process; hence is very different from our tool.
Corner et al reported similar levels of reporting of the date
of consultation between patients’ recall and evidence from
general practice records (Kendall’s tau-b = 0.65) [26].
Strengths and weaknesses
This was an adequately powered RCT with an overall
completion rate of 75%, and hence with a low risk of
bias [27]. As anticipated, there was a higher degree of
missing data in the anxiety domain from the self-
completed group. We did not assess anxiety prior to
administration of the tool, hence there is the possibility
that the anxiety levels in the groups were different at
baseline, Whilst we have assumed that the missing data
were missing completely at random, these individuals
did exhibit a greater degree of anxiety and there could
be a theoretical association between anxiety and comple-
tion. The generalisability of the findings is limited with
regard to ethnicity, as the sample was almost exclusively
white.
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Given the lack of evidence of validation of tools in this
area, we are happy for the Cancer Symptom Interval
Measure (C-SIM) to be used in future descriptive and
epidemiological studies of cancer diagnostic journeys,
and to assess the functioning of current diagnostic service
provision. Given our findings of less anxiety and more
complete data collection in the researcher-completed
group, we would recommend the researcher-administered
approach where feasible. However, this clearly has re-
source implications, and limits its use in population-based
studies. The agreement between patient questionnaires
and GP records was moderate and whilst there was
greater evidence of consultations being recorded in the
GP records, for participants who reported an exact date
rather than an estimated date, for many consultations the
participants were unable to report an exact date, hence
keeping both is probably necessary. Further work is
needed to refine the tool in the light of the emergent find-
ings, as some questions are easier to complete than others.
Further research could also look at what may serve to re-
duce anxiety by researcher-administered forms. This could
include having a professional and supportive presence
when completing the form.Conclusion
We have developed and tested a tool for collecting
patient-reported data relating to appraisal intervals,
help-seeking intervals, and diagnostic intervals in the
cancer diagnostic pathway for 11 separate cancers, and
provided evidence of its acceptability, feasibility and validity.
This is a useful tool to use in descriptive and epidemio-
logical studies of cancer diagnostic journeys, and causes
less anxiety if administered by a researcher.Additional files
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